The stock price of Sarepta Therapeutics Inc (NASDAQ: SRPT) has jumped by 2.42 compared to previous close of 137.28. Despite this, the company has seen a gain of 5.35% in its stock price over the last five trading days. schaeffersresearch.com reported 2024-08-19 that After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
Sarepta Therapeutics Inc (NASDAQ: SRPT) has a price-to-earnings ratio that is above its average at 347.59x. The stock has a 36-month beta value of 0.81. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SRPT is 89.40M, and at present, short sellers hold a 7.51% of that float. On August 20, 2024, the average trading volume of SRPT was 1.93M shares.
SRPT’s Market Performance
SRPT stock saw a decrease of 5.35% in the past week, with a monthly decline of -3.93% and a quarterly a decrease of 7.47%. The volatility ratio for the week is 3.02%, and the volatility levels for the last 30 days are 3.30% for Sarepta Therapeutics Inc (SRPT). The simple moving average for the last 20 days is 0.81% for SRPT’s stock, with a simple moving average of 16.46% for the last 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with RBC Capital Mkts repeating the rating for SRPT by listing it as a “Outperform.” The predicted price for SRPT in the upcoming period, according to RBC Capital Mkts is $182 based on the research report published on July 29, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $176, previously predicting the price at $172. The rating they have provided for SRPT stocks is “Neutral” according to the report published on June 26th, 2024.
Piper Sandler gave a rating of “Overweight” to SRPT, setting the target price at $157 in the report published on May 31st of the current year.
SRPT Trading at -0.89% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.85% of loss for the given period.
Volatility was left at 3.30%, however, over the last 30 days, the volatility rate increased by 3.02%, as shares sank -4.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.08% upper at present.
During the last 5 trading sessions, SRPT rose by +5.41%, which changed the moving average for the period of 200-days by +83.85% in comparison to the 20-day moving average, which settled at $139.12. In addition, Sarepta Therapeutics Inc saw 45.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Chambers Michael Andrew, who purchase 37,038 shares at the price of $133.80 back on Aug 16 ’24. After this action, Chambers Michael Andrew now owns 284,034 shares of Sarepta Therapeutics Inc, valued at $4,955,728 using the latest closing price.
Brown Ryan Edward, the EVP, General Counsel of Sarepta Therapeutics Inc, sale 38,957 shares at $161.61 during a trade that took place back on Jun 25 ’24, which means that Brown Ryan Edward is holding 17,129 shares at $6,296,029 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.88 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.03. The total capital return value is set at 0.01. Equity return is now at value 5.20, with 1.44 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.32. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is -5.15.
Currently, EBITDA for the company is -267.82 million with net debt to EBITDA at 16.3. When we switch over and look at the enterprise to sales, we see a ratio of 9.57. The receivables turnover for the company is 3.84for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.90.
Conclusion
To sum up, Sarepta Therapeutics Inc (SRPT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
